All In Biotech

Drug Trial Radar · NCT06555068

A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors

An Open-Label, Multi-Center Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Other Antitumor Therapies in Patients With Advanced Unresectable or Metastatic Breast Cancer or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

528

Planned (sponsor's estimate)

Start

Aug 12, 2024

Primary completion

Dec 2027

Study completion Aug 2028

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080,or letrozole and trastuzumab, with or without pertuzumab, or HRS-4508 and letrozole, with or without trastuzumab and/or pertuzumab, for advanced unresectable or metastatic breast cancer or HRS-9813 as monotherapy in Patients with Advanced Solid Tumors

Conditions

  • Advanced Unresectable or Metastatic Breast Cancer
  • Advanced Solid Tumors

Interventions

  • HRS-6209 in Combination with FulvestrantDrug

    HRS-6209 in Combination with Fulvestrant

  • HRS-6209 in Combination with HRS-1358Drug

    HRS-6209 in Combination with HRS-1358

  • HRS-6209 in Combination with LetrozoleDrug

    HRS-6209 in Combination with Letrozole

  • HRS-6209 in Combination with HRS-8080Drug

    HRS-6209 in Combination with HRS-8080

  • HRS-6209 in Combination with HRS-1358Drug

    HRS-6209 in Combination with HRS-1358

  • HRS-6209 in Combination with HRS-9813 and LetrozoleDrug

    HRS-6209 in Combination with HRS-9813 and Letrozole

  • HRS-6209 in Combination with HRS-9813 and HRS-8080Drug

    HRS-6209 in Combination with HRS-9813 and HRS-8080

  • HRS-6209 in Combination with letrozole and trastuzumabDrug

    HRS-6209 in Combination with letrozole and trastuzumab

  • HRS-6209 in Combination with letrozole and trastuzumab and pertuzumabDrug

    HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab

  • HRS-6209 in Combination HRS-4508 and letrozoleDrug

    HRS-6209 in Combination HRS-4508 and letrozole

  • HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumabDrug

    HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT (dose-limiting toxicity)-Stage I (dose exploration)Time frame: 28 days after the first dose
  2. MTD (maximum tolerated dose) -Stage I (dose exploration)Time frame: 28 days after the first dose
  3. RP2D (recommended phase II dose) -Stage I (dose exploration)Time frame: 28 days after the first dose
  4. (Serious) AEs-Stage I (dose exploration)Time frame: every week in Cycle 1 (28 days after the first dose), every 2 weeks in Cycle 2 (28 days after the second dose), every 4 weeks from Cycle 3 and thereafter (28 days after each dose), lasting about one year
  5. ORR ( objective response rate )-Stage II (efficacy expansion)Time frame: every 8 weeks lasting about one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.